Iqvia Holdings Inc. Share Price

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse 01:30:02 13/07/2024 am IST 5-day change 1st Jan Change
224.2 USD +2.16% Intraday chart for Iqvia Holdings Inc. +7.72% -3.12%
Sales 2024 * 1.55TCr 1,29200Cr Sales 2025 * 1.65TCr 1,38200Cr Capitalization 4.08TCr 3,41200Cr
Net income 2024 * 133.5Cr 11TCr Net income 2025 * 157.2Cr 13TCr EV / Sales 2024 * 3.4 x
Net Debt 2024 * 1.18TCr 98TCr Net Debt 2025 * 1.12TCr 94TCr EV / Sales 2025 * 3.15 x
P/E ratio 2024 *
30.6 x
P/E ratio 2025 *
25.7 x
Employees 87,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.16%
1 week+7.72%
Current month+6.02%
1 month+4.77%
3 months-4.29%
6 months+4.83%
Current year-3.12%
More quotes
1 week
207.07
Extreme 207.07
224.97
1 month
205.06
Extreme 205.06
224.97
Current year
205.06
Extreme 205.06
261.73
1 year
167.42
Extreme 167.42
261.73
3 years
165.75
Extreme 165.75
285.61
5 years
81.79
Extreme 81.79
285.61
10 years
51.09
Extreme 51.09
285.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 03/16/03
Director of Finance/CFO 63 01/20/01
Chief Operating Officer 51 01/17/01
Members of the board TitleAgeSince
Director/Board Member 67 03/16/03
Director/Board Member 68 27/17/27
Chief Executive Officer 63 03/16/03
More insiders
Date Price Change Volume
12/24/12 224.2 +2.16% 1,362,151
11/24/11 219.4 +3.52% 1,124,660
10/24/10 212 -0.50% 888,236
09/24/09 213 +1.97% 1,123,299
08/24/08 208.9 +0.40% 1,287,096

Delayed Quote Nyse, July 13, 2024 at 01:30 am IST

More quotes
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
224.2 USD
Average target price
269.2 USD
Spread / Average Target
+20.11%
Consensus